Sirtex: Don’t wait until it’s too late
Sirtex - SIRFLOX presentation at ASCO and initial positive feedback from physicians has done little to change our view that while SIR-Spheres microspheres works in the liver, as expected from a locoregional therapy, the results will have limited impact on driving adoption in first-line metastatic colorectal cancer (mCRC). With the most amenable patient population to treatment unknown, we would use share strength to exit positions as we do not believe these data will translate into a significant increase in near-term sales. We make no changes to our estimates (SRX, Reduce, Price Target A$13.42). Report attached .
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
No areas of expertise